Details of the Drug
General Information of Drug (ID: DMTZ7E4)
| Drug Name |
SC-106
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
SC-106; AC1LAPZA; SCHEMBL6773940; IABCGGIFHPDBCJ-JTQLQIEISA-N; (3R)-3-[[2-[(3-guanidinobenzoyl)amino]acetyl]amino]pent-4-ynoic acid; (R)-3-(2-{[1-(3-Guanidino-phenyl)-methanoyl]-amino}-ethanoylamino)-pent-4-ynoic acid; (3R)-3-[[2-[[3-(diaminomethylideneamino)benzoyl]amino]acetyl]amino]pent-4-ynoic acid
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 331.33 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -1.3 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 7 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 5 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| ICD Disease Classification | 15 Disease of the musculoskeletal system/connective tissue | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Class | ICD-11: FA20 Rheumatoid arthritis | |||||||||||||||||
| The Studied Tissue | Synovial tissue | |||||||||||||||||
| The Studied Disease | Rheumatoid arthritis [ICD-11:FA20] | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


